Abstract | OBJECTIVE: To evaluate and validate the recent and emerging data for prognostic and predictive biomarkers with therapeutic targets in breast cancer. DATA SOURCES: A literature search from January 2015 to March 2022 was performed using the key terms breast cancer, clinical practice guidelines, gene mutations, genomic assay, immune cancer therapy, predictive and/or prognostic biomarkers, and targeted therapies. STUDY SELECTION AND DATA EXTRACTION: Relevant clinical trials, meta-analyses, seminal articles, and published evidence- and consensus-based clinical practice guidelines in the English language were identified, reviewed and evaluated. DATA SYNTHESIS: CONCLUSIONS:
Biomarker-driven therapies have the potential to confer greater therapeutic advantages than standard-of-care therapies. The purported survival benefits associated with biomarker-driven therapies should be weighed against their potential harms.
|
Authors | Clement Chung, Vanessa T Y Yeung, Kenneth C W Wong |
Journal | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
(J Oncol Pharm Pract)
Vol. 29
Issue 6
Pg. 1343-1360
(Sep 2023)
ISSN: 1477-092X [Electronic] England |
PMID | 35971313
(Publication Type: Journal Article)
|
Chemical References |
- BRCA1 protein, human
- BRCA1 Protein
- Biomarkers, Tumor
- BRCA2 protein, human
- BRCA2 Protein
|
Topics |
- Humans
- Female
- Prognosis
- Breast Neoplasms
(genetics)
- BRCA1 Protein
(genetics)
- Microsatellite Instability
- Biomarkers, Tumor
(genetics, metabolism)
- BRCA2 Protein
(genetics)
|